Experimental studies in rodents demonstrated that JD5037 was effective in mitigating both diabetic nephropathy by blocking overactive CB1R in podocytes (15) and regulating renal GLUT2 in proximal tubular cells (18) and obesity-induced nephropathy by blocking overactive CB1R in proximal tubular cells (16). This evidence concerns the gene CNR1 and diabetic kidney disease.